P70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 6, 2013, Pages 1316-1328

  Piedfer, Marion ^a   Bouchet, Sandrine ^a,b   Tang, Ruoping ^a,b   Billard, Christian ^a   Dauzonne, Daniel ^c,d   Bauvois, Brigitte ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSTITUT CURIE   (France)

^d CNRS   (France)

Author keywords

Apoptosis; Bax; Caspase; Myeloid cell; P70S6K; Proteasome

Indexed keywords

3,3' DIAMINO 4' METHOXYFLAVONE; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; FLAVONE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEASOME INHIBITOR; PROTEIN BAD; PROTEIN BAX; S6 KINASE; THREONINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; BLOOD CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MONOCYTE MACROPHAGE PRECURSOR CELL; MYELOBLAST; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BORONIC ACIDS; CASPASES; CELL CYCLE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOID, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; PHOSPHORYLATION; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TUMOR CELLS, CULTURED;

EID: 84875765575     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.02.016     Document Type: Article

References (80)

1. King M.E., Rowe J.M. Recent developments in acute myelogenous leukemia therapy. Oncologist 2007, 12(Suppl. 2):14-21.
2. Robak T., Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin. Ther. 2009, 31(Pt 2):2349-2370.
3. Khan N., Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008, 269:269-280.
4. Birt D.F., Hendrich S., Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 2001, 90:157-177.
5. Li Y., Fang H., Xu W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem. 2007, 7:663-678.
6. Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today 2010, 15:757-765.
7. Aggarwal B.B., Takada Y., Oommen O.V. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin. Investig. Drugs 2004, 13:1327-1338.
8. Williams R.J., Spencer J.P., Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radic. Biol. Med. 2004, 36:838-849.
9. Hou D.X., Kumamoto T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid. Redox Signal. 2010, 13:691-719.
10. Newcomb E.W. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004, 15:411-419.
11. Cheng S., Gao N., Zhang Z., Chen G., Budhraja A., Ke Z., Son Y.O., Wang X., Luo J., Shi X. Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax. Clin. Cancer Res. 2010, 16:5679-5691.
12. Yu C., Rahmani M., Dai Y., Conrad D., Krystal G., Dent P., Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. 2003, 63:1822-1833.
13. Rosato R.R., Dai Y., Almenara J.A., Maggio S.C., Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 2004, 18:1780-1788.
14. Blum W., Phelps M.A., Klisovic R.B., Rozewski D.M., Ni W., Albanese K.A., Rovin B., Kefauver C., Devine S.M., Lucas D.M., Johnson A., Schaaf L.J., Byrd J.C., Marcucci G., Grever M.R. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 2010, 95:1098-1105.
15. Karp J.E., Smith B.D., Resar L.S., Greer J.M., Blackford A., Zhao M., Moton-Nelson D., Alino K., Levis M.J., Gore S.D., Joseph B., Carraway H., McDevitt M.A., Bagain L., Mackey K., Briel J., Doyle L.A., Wright J.J., Rudek M.A. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011, 117:3302-3310.
16. Dauzonne D., Folleas B., Martinez L., Chabot G.G. Synthesis and in vitro cytotoxicity of a series of 3-aminoflavones. Eur. J. Med. Chem. 1997, 32:71-82.
17. Bauvois B., Puiffe M.L., Bongui J.B., Paillat S., Monneret C., Dauzonne D. Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13. J. Med. Chem. 2003, 46:3900-3913.
18. Piedfer M., Dauzonne D., Tang R., N'Guyen J., Billard C., Bauvois B. Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 2011, 25:2831-2842.
19. Quiney C., Dauzonne D., Kern C., Fourneron J.D., Izard J.C., Mohammad R.M., Kolb J.P., Billard C. Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. Leuk. Res. 2004, 28:851-861.
20. Quentmeier H., Martelli M.P., Dirks W.G., Bolli N., Liso A., Macleod R.A., Nicoletti I., Mannucci R., Pucciarini A., Bigerna B., Martelli M.F., Mecucci C., Drexler H.G., Falini B. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005, 19:1760-1767.
21. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991, 77:1080-1086.
22. Bhardwaj A., Sethi G., Vadhan-Raj S., Bueso-Ramos C., Takada Y., Gaur U., Nair A.S., Shishodia S., Aggarwal B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109:2293-2302.
23. Oster W., Mertelsmann R., Herrmann F. Role of colony-stimulating factors in the biology of acute myelogenous leukemia. Int. J. Cell Cloning 1989, 7:13-29.
24. Papa V., Tazzari P.L., Chiarini F., Cappellini A., Ricci F., Billi A.M., Evangelisti C., Ottaviani E., Martinelli G., Testoni N., McCubrey J.A., Martelli A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008, 22:147-160.
25. Faderl S., Pal A., Bornmann W., Albitar M., Maxwell D., Van Q., Peng Z., Harris D., Liu Z., Hazan-Halevy I., Kantarjian H.M., Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009, 69:3910-3917.
26. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
27. Quiney C., Billard C., Faussat A.M., Salanoubat C., Ensaf A., Nait-Si Y., Fourneron J.D., Kolb J.P. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006, 20:491-497.
28. Sanceau J., Boyd D.D., Seiki M., Bauvois B. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J. Biol. Chem. 2002, 277:35766-35775.
29. Decker R.H., Dai Y., Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ. 2001, 8:715-724.
30. Wang Z.B., Liu Y.Q., Cui Y.F. Pathways to caspase activation. Cell Biol. Int. 2005, 29:489-496.
31. Westphal D., Dewson G., Czabotar P.E., Kluck R.M. Molecular biology of Bax and Bak activation and action. Biochim. Biophys. Acta 2011, 1813:521-531.
32. Song G., Chen G.G., Hu T., Lai P.B. Bid stands at the crossroad of stress-response pathways. Curr. Cancer Drug Targets 2010, 10:584-592.
33. Zhao S., Konopleva M., Cabreira-Hansen M., Xie Z., Hu W., Milella M., Estrov Z., Mills G.B., Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004, 18:267-275.
34. Martelli A.M., Nyakern M., Tabellini G., Bortul R., Tazzari P.L., Evangelisti C., Cocco L. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006, 20:911-928.
35. Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9666-9670.
36. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 2008, 11:63-76.
37. Dhar R., Persaud S.D., Mireles J.R., Basu A. Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis. Biochemistry 2009, 48:1474-1480.
38. Li X., Wood T.E., Sprangers R., Jansen G., Franke N.E., Mao X., Wang X., Zhang Y., Verbrugge S.E., Adomat H., Li Z.H., Trudel S., Chen C., Religa T.L., Jamal N., Messner H., Cloos J., Rose D.R., Navon A., Guns E., Batey R.A., Kay L.E., Schimmer A.D. Effect of noncompetitive proteasome inhibition on bortezomib resistance. J. Natl. Cancer Inst. 2010, 102:1069-1082.
39. Duncan J.S., Turowec J.P., Vilk G., Li S.S., Gloor G.B., Litchfield D.W. Regulation of cell proliferation and survival: convergence of protein kinases and caspases. Biochim. Biophys. Acta 2010, 1804:505-510.
40. Perl A.E., Carroll M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr. Treat. Options Oncol. 2007, 8:265-276.
41. Liao Y., Hung M.C. Physiological regulation of Akt activity and stability. Am. J. Transl. Res. 2010, 2:19-42.
42. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
43. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
44. Fenton T.R., Gout I.T. Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 2011, 43:47-59.
45. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
46. Renault T.T., Manon S. Bax: addressed to kill. Biochimie 2011, 93:1379-1391.
47. Hsu Y.T., Youle R.J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J. Biol. Chem. 1998, 273:10777-10783.
48. Scaffidi C., Schmitz I., Zha J., Korsmeyer S.J., Krammer P.H., Peter M.E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 1999, 274:22532-22538.
49. Liu L.Z., Zhou X.D., Qian G., Shi X., Fang J., Jiang B.H. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007, 67:6325-6332.
50. An W.G., Hwang S.G., Trepel J.B., Blagosklonny M.V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14:1276-1283.
51. Oerlemans R., Franke N.E., Assaraf Y.G., Cloos J., van Zantwijk I., Berkers C.R., Scheffer G.L., Debipersad K., Vojtekova K., Lemos C., van der Heijden J.W., Ylstra B., Peters G.J., Kaspers G.L., Dijkmans B.A., Scheper R.J., Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
52. Fennell D.A., Chacko A., Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008, 27:1189-1197.
53. Fuchs O., Provaznikova D., Marinov I., Kuzelova K., Spicka I. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc. Hematol. Disord. Drug Targets 2009, 9:62-77.
54. Hutter G., Zimmermann Y., Rieken M., Hartmann E., Rosenwald A., Hiddemann W., Dreyling M. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL. Leukemia 2012, 26:2442-2444.
55. Laussmann M.A., Passante E., Dussmann H., Rauen J.A., Wurstle M.L., Delgado M.E., Devocelle M., Prehn J.H., Rehm M. Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8. Cell Death Differ. 2011, 18:1584-1597.
56. Russo A., Bronte G., Fulfaro F., Cicero G., Adamo V., Gebbia N., Rizzo S. Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr. Cancer Drug Targets 2010, 10:55-67.
57. Heine A., Held S.A., Bringmann A., Holderried T.A., Brossart P. Immunomodulatory effects of anti-angiogenic drugs. Leukemia 2011, 25:899-905.
58. Ko J.K., Choi C.H., Kim Y.K., Kwon C.H. The proteasome inhibitor MG-132 induces AIF nuclear translocation through down-regulation of ERK and Akt/mTOR pathway. Neurochem. Res. 2011, 36:722-731.
59. Befani C.D., Vlachostergios P.J., Hatzidaki E., Patrikidou A., Bonanou S., Simos G., Papandreou C.N., Liakos P. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. (Berl.) 2012, 90:45-54.
60. Dalla Via L., Nardon C., Fregona D. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Med. Chem. 2012, 4:525-543.
61. Goel A., Spitz D.R., Weiner G.J. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J. Cell. Biochem. 2012, 113:419-425.
62. Frankland-Searby S., Bhaumik S.R. The 26S proteasome complex: an attractive target for cancer therapy. Biochim. Biophys. Acta 2012, 1825:64-76.
63. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
64. Servida F., Soligo D., Delia D., Henderson C., Brancolini C., Lombardi L., Deliliers G.L. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 2005, 19:2324-2331.
65. Horton T.M., Gannavarapu A., Blaney S.M., D'Argenio D.Z., Plon S.E., Berg S.L. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 2006, 58:13-23.
66. Stapnes C., Doskeland A.P., Hatfield K., Ersvaer E., Ryningen A., Lorens J.B., Gjertsen B.T., Bruserud O. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br. J. Haematol. 2007, 136:814-828.
67. + immature phenotype. Haematologica 2008, 93:57-66.
68. Matondo M., Bousquet-Dubouch M.P., Gallay N., Uttenweiler-Joseph S., Recher C., Payrastre B., Manenti S., Monsarrat B., Burlet-Schiltz O. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk. Res. 2010, 34:498-506.
69. Riccioni R., Senese M., Diverio D., Riti V., Buffolino S., Mariani G., Boe A., Cedrone M., Lo-Coco F., Foa R., Peschle C., Testa U. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br. J. Haematol. 2007, 139:194-205.
70. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., Jordan C.T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16220-16225.
71. Cortes J., Thomas D., Koller C., Giles F., Estey E., Faderl S., Garcia-Manero G., McConkey D., Ruiz S.L., Guerciolini R., Wright J., Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 2004, 10:3371-3376.
72. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., Johri A.R., Jones P.E., Ivanova A., Van Deventer H.W., Gabriel D.A., Shea T.C., Mitchell B.S., Adams J., Esseltine D.L., Trehu E.G., Green M., Lehman M.J., Natoli S., Collins J.M., Lindley C.M., Dees E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
73. Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., Wadleigh M., Ballen K.K., McAfee S., Miller K.B., Levine J., Galinsky I., Trehu E.G., Schenkein D., Neuberg D., Stone R.M., Amrein P.C. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin. Cancer Res. 2008, 14:1446-1454.
74. Rushworth S.A., Bowles K.M., MacEwan D.J. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res. 2011, 71:1999-2009.
75. Fortier J.M., Graubert T.A. Murine models of human acute myeloid leukemia. Cancer Treat. Res. 2010, 145:183-196.
76. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114:1545-1552.
77. Chen Y.F., Yang J.S., Huang W.W., Tsai H.Y. Novel anti-leukemia activities of pipoxolan operate via the mitochondria-related pathway in human leukemia U937 cells and attenuate U937 cell growth in an animal model. Mol. Med. Rep. 2010, 3:851-856.
78. Miller C.P., Manton C.A., Hale R., Debose L., Macherla V.R., Potts B.C., Palladino M.A., Chandra J. Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs. Chem. Biol. Interact. 2011, 194:58-68.
79. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl. Cancer Inst. 2011, 103:1007-1017.
80. Mujtaba T., Dou Q.P. Black tea polyphenols inhibit tumor proteasome activity. In Vivo 2012, 26:197-202.